psilocybin treatment  (Compass Pathways Ltd)

Journal: Expert opinion on pharmacotherapy

Article Title: Pharmacotherapeutic strategies for the treatment of anorexia nervosa – novel targets to break a vicious cycle

doi: 10.1080/14656566.2024.2424316

Figure Lengend Snippet: Novel treatments to target anorexia nervosa core and associated behaviors.

Article Snippet: Of note, Johns Hopkins University ( NCT04052568 ) and Imperial College London ( NCT04505189 ) have completed clinical trials assessing the use of psilocybin in AN treatment.

Techniques: Drug discovery, Activity Assay, Concentration Assay

Journal: Medicina

Article Title: The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials

doi: 10.3390/medicina61020278

Figure Lengend Snippet: Details of studies.

Article Snippet: A. Garcia-Romeu (USA) [ ] , Smoking biomarkers, TLFB, QSU, SASE, HRS, SOCQ, Mysticism scale , Johns Hopkins University , Psilocybin treatment resulted in significant long-term smoking cessation success , Two to three psilocybin sessions (20 mg/70 kg and 30 mg/70 kg), integrated with 15 weeks of CBT and mindfulness-based techniques for smoking cessation.

Techniques:

Journal: Medicina

Article Title: The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials

doi: 10.3390/medicina61020278

Figure Lengend Snippet: Psychedelic-Assisted Therapies for Substance Use Disorders and Behavioral Addictions—Key Studies and Findings.

Article Snippet: A. Garcia-Romeu (USA) [ ] , Smoking biomarkers, TLFB, QSU, SASE, HRS, SOCQ, Mysticism scale , Johns Hopkins University , Psilocybin treatment resulted in significant long-term smoking cessation success , Two to three psilocybin sessions (20 mg/70 kg and 30 mg/70 kg), integrated with 15 weeks of CBT and mindfulness-based techniques for smoking cessation.

Techniques: Drug discovery, Clinical Proteomics, Concentration Assay, Transformation Assay

Journal: Frontiers in Pharmacology

Article Title: Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

doi: 10.3389/fphar.2022.927984

Figure Lengend Snippet: An overview of the characteristics of psilocybin. The diagram includes the chemical structures of psilocybin and its metabolite. The bold lines indicate similarities in the chemical structure between this psychedelic and serotonin. In addition, the enzymes and major organs involved in the metabolism and excretion of psilocybin are indicated. The mechanism of action represents the targets of the psychedelic, both the region of the brain affected by the psychedelic and the receptors with which it interacts (pink circle for agonist). 5HT—serotonin receptors (2Ar, 1Ar, 2Cr, – subtypes). IP3, inositol-3-phosphate; cAMP, cyclic adenosine monophosphate.

Article Snippet: The US Food and Drug Administration (FDA) awarded “breakthrough therapy” status to a psilocybin treatment developed by London-based Compass Pathways Ltd. for TRD, advancing the development process in 2018 ( ).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

doi: 10.3389/fphar.2022.927984

Figure Lengend Snippet: The common adverse effects related to psilocybin exposure.

Article Snippet: The US Food and Drug Administration (FDA) awarded “breakthrough therapy” status to a psilocybin treatment developed by London-based Compass Pathways Ltd. for TRD, advancing the development process in 2018 ( ).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders

doi: 10.3389/fphar.2022.927984

Figure Lengend Snippet: An overview of the characteristics of DMT. The diagram includes the chemical structures of DMT and its metabolite. The bold lines indicate similarities in the chemical structure between this psychedelic and serotonin. In addition, the enzymes and major organs involved in the metabolism and excretion of psilocybin are indicated. The mechanism of action represents the targets of the psychedelic, both the region of the brain affected by the psychedelic and the receptors with which it interacts (pink circle for agonist). 5HT—serotonin receptors (2Ar, 2Cr,—subtypes), sigma 1 receptor. MAOI, monoamine oxidase I; IP3, inositol-3-phosphate; ER, endoplasmic reticulum.

Article Snippet: The US Food and Drug Administration (FDA) awarded “breakthrough therapy” status to a psilocybin treatment developed by London-based Compass Pathways Ltd. for TRD, advancing the development process in 2018 ( ).

Techniques:

Journal: Molecules

Article Title: The Therapeutic Potential of Psilocybin

doi: 10.3390/molecules26102948

Figure Lengend Snippet: The potential therapeutic window of psilocybin-assisted therapy, that is, diseased states in which psilocybin-assisted therapy is being explored.

Article Snippet: 3. , Usona Institute (Wisconsin, USA). , 2018—U.S. Food and Drug Administration (USFDA) approval for a psilocybin treatment for major depressive disorder (MDD) , [ ] .

Techniques: Cannabis

Journal: Molecules

Article Title: The Therapeutic Potential of Psilocybin

doi: 10.3390/molecules26102948

Figure Lengend Snippet: Major institutes and organizations involved in psilocybin research.

Article Snippet: 3. , Usona Institute (Wisconsin, USA). , 2018—U.S. Food and Drug Administration (USFDA) approval for a psilocybin treatment for major depressive disorder (MDD) , [ ] .

Techniques: Functional Assay, Comparison, Positron Emission Tomography